PDCD1 and cancer: Nevertheless, the observation that cancer patients with non-mutated BRCA and non-defective HR might derive higher benefit from PARPi-ICIs combination (ORR 19%) than expected from either agent as monotherapy (ORR 0-4% or 4-10% with PARPi or anti-PD-1/PD-L1 mAbs, respectively) [286], suggests that additional mechanisms (e.g., modulation of gene transcription) not directly related to PARPi-induced DNA damage might account for PARPi/ICIs synergism.